Company news
Fulcrum Therapeutics, Inc. news in 2023
Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 8, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 6, 2023
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8: 00 a.m. ET
October 30, 2023
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 21, 2023
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 6, 2023
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
August 21, 2023
Fulcrum Therapeutics Appoints Chief Financial Officer
August 2, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
August 2, 2023
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8: 00 a.m. ET
July 26, 2023
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
July 9, 2023
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
May 14, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
May 14, 2023
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8: 00 a.m. ET
May 7, 2023
Fulcrum Therapeutics Announces CFO Resignation
April 4, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
March 8, 2023
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8: 00 a.m. ET
March 5, 2023
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
February 23, 2023
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
February 7, 2023
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
January 16, 2023
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 16, 2023
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
January 3, 2023
Fulcrum Therapeutics Announces CEO Transition
January 3, 2023
Calls in 2023
- Fulcrum Therapeutics (NASDAQ:FULC) Q3 2023 Earnings Call
Nov 7, 2023
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q2 2023 Earnings Call
Aug 3, 2023
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q1 2023 Earnings Call
May 15, 2023
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q4 2022 Earnings Call
Mar 9, 2023
Transcript
Decks in 2023
- Corporate Update (August 2023)
Corporate update · 12 slides · Aug 22, 2023
- Corporate Update (January 2023)
Corporate update · 16 slides · Jan 4, 2023